Contents

Current Medicinal Chemistry - Anti-Cancer Agents, Volume 3 - Number 5

Preface [ Hot Topic: Radiation Oncology as Mainstay of Modern Cancer Medicine (Guest Editors: Claus Belka & Verena Jendrossek)]

, 3(5): ii

Claus Belka and Verena Jendrossek


DOI: 10.2174/15680118103030500ii




Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy

, 3(5): 319 - 326

Dilek Guner, Claus Belka and Peter T. Daniel


DOI: 10.2174/1568011033482369




Anti-Epidermal Growth Factor Receptor Strategies to Enhance Radiation Action

, 3(5): 327 - 333

G. Lammering


DOI: 10.2174/1568011033482323




Death Receptor Ligands: New Strategies for Combined Treatment with Ionizing Radiation

, 3(5): 334 - 342

Patrizia Marini and Claus Belka


DOI: 10.2174/1568011033482297




Membrane Targeted Anticancer Drugs: Potent Inducers of Apoptosis and Putative Radiosensitisers

, 3(5): 343 - 353

V. Jendrossek and R. Handrick


DOI: 10.2174/1568011033482341




New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2

, 3(5): 354 - 359

Cordula Petersen, Michael Baumann and Sven Petersen


DOI: 10.2174/1568011033482314




Radioprotection of Normal Tissue to Improve Radiotherapy: The Effect of the Bowman Birk Protease Inhibitor

, 3(5): 360 - 363

K. H. Dittmann, C. Mayer and H. P. Rodemann


DOI: 10.2174/1568011033482288




Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology

, 3(5): 364 - 374

Martin Weinmann, Stefan Welz and Michael Bamberg


DOI: 10.2174/1568011033482350




Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?

, 3(5): 375 - 382

Johannes Classen and Wilfried Budach


DOI: 10.2174/1568011033482305




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science